Häuser Winfried, Arnold Bernhard, Eich Wolfgang, Felde Eva, Flügge Christl, Henningsen Peter, Herrmann Markus, Köllner Volker, Kühn Edeltraud, Nutzinger Detlev, Offenbächer Martin, Schiltenwolf Marcus, Sommer Claudia, Thieme Kati, Kopp Ina
Department of Internal Medicine I, Klinikum Saarbrücken, Germany.
Ger Med Sci. 2008 Dec 9;6:Doc14.
The prevalence of fibromyalgia syndrome (FMS) of 1-2% in the general population associated with high disease-related costs and the conflicting data on treatment effectiveness had led to the development of evidence-based guidelines designed to provide patients and physicians guidance in selecting among the alternatives. Until now no evidence-based interdisciplinary (including patients) guideline for the management of FMS was available in Europe. Therefore a guideline for the management of fibromyalgia syndrome (FMS) was developed by 13 German medical and psychological associations and two patient self-help organisations. The task was coordinated by two German scientific umbrella organisations, the Association of the Scientific Medical Societies in Germany AWMF and the German Interdisciplinary Association of Pain Therapy DIVS. A systematic search of the literature including all controlled studies, systematic reviews and meta-analyses of pharmacological and non-pharmacological treatments of FMS was performed in the Cochrane Library (1993-12/2006), Medline (1980-12/2006), PsychInfo (1966-12/2006) and Scopus (1980-12/ 2006). Levels of evidence were assigned according to the classification system of the Oxford-Centre for Evidence Based Medicine. Grading of the strengths of recommendations was done according to the German program for disease management guidelines. Standardized procedures were used to reach a consensus on recommendations. The guideline was reviewed and finally approved by the boards of the societies involved and published online by the AWMF on april 25, 2008: http://www.uni-duesseldorf.de/AWMF/ll/041-004.htm. A short version of the guideline for patients is available as well: http://www.uni-duesseldorf.de/AWMF/ll/041-004p.htm. The following procedures in the management of fms were strongly recommended: information on diagnosis and therapeutic options and patient-centered communication, aerobic exercise, cognitive and operant behavioural therapy, multicomponent treatment and amitriptyline. Based on expert opinion, a stepwise FMS-management was proposed. Step 1 comprises confirming the diagnosis and patient education and treatment of physical or mental comorbidities or aerobic exercise or cognitive behavioural therapy or amitriptyline. Step 2 includes multicomponent treatment. Step 3 comprises no further treatment or self-management (aerobic exercise, stress management) and/or booster multicomponent therapy and/or pharmacological therapy (duloxetine or fluoxetine or paroxetine or pregabalin or tramadol/aminoacetophen) and/or psychotherapy (hypnotherapy or written emotional disclosure) and/or physical therapy (balneotherapy or whole body heat therapy) and/or complementary therapies (homeopathy or vegetarian diet). The choice of treatment options should be based on informed decision-making and respect of the patients' preferences.
纤维肌痛综合征(FMS)在普通人群中的患病率为1%-2%,这与高昂的疾病相关费用以及治疗效果方面相互矛盾的数据有关,这促使了循证指南的制定,旨在为患者和医生在多种治疗方案中进行选择时提供指导。到目前为止,欧洲尚无基于循证的跨学科(包括患者)FMS管理指南。因此,由13个德国医学和心理学协会以及两个患者自助组织制定了纤维肌痛综合征(FMS)管理指南。该任务由两个德国科学总括组织协调,即德国科学医学协会联合会(AWMF)和德国疼痛治疗跨学科协会(DIVS)。在考克兰图书馆(1993年-2006年12月)、医学索引数据库(1980年-2006年12月)、心理学文摘数据库(1966年-2006年12月)和Scopus数据库(1980年-2006年12月)中对包括所有对照研究、系统评价以及FMS药物和非药物治疗的荟萃分析在内的文献进行了系统检索。根据牛津循证医学中心的分类系统确定证据级别。根据德国疾病管理指南计划对推荐强度进行分级。采用标准化程序就推荐达成共识。该指南经相关协会理事会审查并最终批准,由AWMF于2008年4月25日在线发布:http://www.uni-duesseldorf.de/AWMF/ll/041-004.htm。也有面向患者的指南简短版本:http://www.uni-duesseldorf.de/AWMF/ll/041-004p.htm。强烈推荐FMS管理中的以下程序:关于诊断和治疗选择的信息以及以患者为中心的沟通、有氧运动、认知和操作性行为疗法、多成分治疗以及阿米替林。基于专家意见,提出了FMS的逐步管理方法。第一步包括确诊、患者教育以及对身体或精神合并症的治疗,或有氧运动,或认知行为疗法,或阿米替林治疗。第二步包括多成分治疗。第三步包括不再进一步治疗或自我管理(有氧运动、压力管理)和/或强化多成分治疗和/或药物治疗(度洛西汀或氟西汀或帕罗西汀或普瑞巴林或曲马多/对乙酰氨基酚)和/或心理治疗(催眠疗法或书面情感宣泄)和/或物理治疗(浴疗法或全身热疗)和/或补充疗法(顺势疗法或素食饮食)。治疗方案的选择应基于知情决策并尊重患者的偏好。